• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Artificial Organs >SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update
【24h】

SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update

机译：划伤（Pegymated Carboxyhemoglobin牛）：作用机制和临床更新

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Historically, blood substitutes were under development that would provide oxygen carrying capacity as well as fluid replacement for both trauma and surgical indications. Their development was halted by the inability of the products to deliver therapeutic amounts of oxygen targeted to hypoxic tissue as well as from the inherent toxicity of the molecules. This led to the concept of an oxygen therapeutic that would be targeted for indications caused by anemia/ischemia/hypoxia but would not exhibit the toxicity that plagued earlier products. The complex pathophysiology of diseases such as sickle cell and hemorrhagic stroke not only has hypoxia as a pivotal event but also includes inflammation and vasoconstriction that perpetuate the oxygen deprivation. There is a need for an effective therapeutic that addresses the multiple events of inflammation and oxygen deprivation. SANGUINATE acts as a dual mode carbon monoxide (CO) and oxygen delivery therapeutic. SANGUINATE is designed not only to treat hypoxia but also to act on concurrent pathologies such as inflammation and reperfusion injury. This expands the potential therapeutic utility of SANGUINATE beyond anemia into indications such as early brain injury and delayed kidney graft function, where inflammation plays a pivotal pathological role as well as in indications such as sickle cell disease where the inflammation and hypoxia contribute to the development of comorbidities such as vaso-occlusive crisis. Clinical trials in multiple indications are underway.
机译：从历史上看，正在开发血液替代品，这将提供氧气携带能力以及对创伤和外科手术的液体更换。它们的发展被产品无法达到靶向缺氧组织的治疗量的氧气以及分子的固有毒性。这导致了氧气治疗的概念，该氧气治疗症将针对贫血/缺血/缺氧引起的适应症，但不会表现出困扰早期产品的毒性。诸如镰状细胞和出血性中风等疾病的复杂病理生理学不仅具有缺氧作为关键事件，还包括炎症和血管收缩，这使得缺氧剥夺。需要一种有效的治疗方法，可以解决炎症和氧缺乏的多个事件。突出用作双模一氧化碳（CO）和氧递送治疗。血管不仅设计不仅要治疗缺氧，还设计用于并发病理，例如炎症和再灌注损伤。这扩大了血管血症超越贫血的潜在治疗效用，进入早期脑损伤和延迟的肾移植功能，其中炎症起到焦虑的病理作用以及诸如令人炎症和缺氧的镰状细胞疾病的适应症以及vaso-encuclusive危机等合并症。正在进行多种适应症的临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号